Akadeum Life Sciences Submits Drug Master File to FDA
Akadeum Life Sciences, a pioneer in buoyant cell separation technology, recently made a significant announcement about their commitment to high-quality cell isolation solutions. They have submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for their GMP BACS™ Microbubble Cell Separation products. This step showcases Akadeum's dedication to supporting the clinical trial endeavors of their customers with cutting-edge microbubble technology.
Committed to Quality Standards
As part of their rigorous approach to product development, Akadeum has undergone successful customer audits in line with US and EU Good Manufacturing Practices (GMP). Their products meet strict standards concerning endotoxin levels, sterility, and viral safety as mandated by the United States Pharmacopeia (USP) and International Council for Harmonization (ICH). This dedication extends to compliance with various ISO quality standards, which facilitates their aim of providing high safety and reliability in cell therapy workflows.
Advancements in Cell Therapy Workflows
Akadeum's proprietary microbubble technology has revolutionized the way researchers separate cells. By leveraging buoyancy, their microbubbles gently elevate non-target cells, allowing untouched target cells to be collected seamlessly. This innovative method reduces the dependency on additional cell separation equipment, lowering the overall costs for facilities and improving cell viability. The expedited workflow not only enhances productivity but also contributes significantly to the quality of cell therapy.
Supporting Developers in Clinical Trials
The introduction of the Drug Master File signifies Akadeum’s proactive stance in aiding cell therapy developers. Vanessa Kelchner, Akadeum's Chief Operating Officer, emphasized the importance of this milestone, stating, "This submission underscores our commitment to maintaining excellence in GMP and the high standards expected by regulatory authorities. Our collaboration with partners enables us to deliver the safest and most effective materials for cell therapy applications." Akadeum is enthusiastic about the role their technology will play in enhancing the field of cell therapy, making it more accessible to patients.
Achieving Cost Efficiencies
One of the key advantages of Akadeum's microbubble technology is the cost efficiency it brings to cell therapy workflows. Facilities using this technology report:
- Shorter Expansion Time: The expansion time has been successfully cut from 9 days to just 5, mitigating the risk of cellular exhaustion and leading to up to a 30% decrease in facility and labor costs.
- Lower Failure Rate: The gentle buoyancy-based cell separation occurs in under an hour, promoting healthier cells and enhancing their potency.
- Decentralized Implementation: The technology supports modular manufacturing processes applicable within a single day, with reported cost savings of up to 75% on equipment.
- Overall Savings: Facilities can achieve total savings of up to 40% in their workflows, significantly supporting the goal of making therapeutics more affordable for broader access.
With the Drug Master File in place, Akadeum empowers therapy developers and manufacturers to enhance their therapeutic capabilities while managing costs, backed by strong regulatory support.
About Akadeum Life Sciences
At the core of Akadeum Life Sciences' mission is a commitment to advancing cell separation technology through their innovative buoyant microbubble platform. This approach enables researchers to achieve better yields and improved simplicity across numerous life science applications. Their goal is to contribute to human health advancements by providing tools that lead to breakthroughs in diagnostics and therapeutics. Find more information about their work at www.akadeum.com.
Contact Akadeum Life Sciences
For inquiries regarding the Drug Master File or other information, feel free to reach out to Brandon McNaughton, PhD, Chief Executive Officer of Akadeum Life Sciences.
Frequently Asked Questions
What is a Drug Master File (DMF)?
A DMF is a regulatory submission that provides detailed information about facilities, processes, or articles used in the manufacturing of drugs. It helps ensure compliance with FDA standards.
What are the benefits of Akadeum's microbubble technology?
It enables faster, more efficient cell separation, reduces operational costs, and enhances cell viability in therapeutic applications.
How does Akadeum ensure product safety?
Akadeum conducts regular audits and adheres to strict GMP, USP, and ICH standards, ensuring their products meet the highest safety and quality benchmarks.
Who can benefit from Akadeum's products?
Researchers, pharmaceutical companies, and clinical trial participants can all benefit from the improved efficiency and reliability offered by Akadeum’s separation technologies.
How can I get more information about Akadeum's offerings?
For detailed information about their products and services, please visit their official website at www.akadeum.com.
